Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC–MS/MS with electrospray ionization: Assay development, validation and application to a clinical study
- 15 September 2005
- journal article
- Published by Elsevier BV in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 39 (3-4), 661-669
- https://doi.org/10.1016/j.jpba.2005.05.005
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteersClinical Therapeutics, 2003
- A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteersClinical Therapeutics, 2003
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)The American Journal of Cardiology, 2003
- Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairmentEuropean Journal of Clinical Pharmacology, 2003
- Rosuvastatin: A Highly Effective New HMG‐CoA Reductase InhibitorCardiovascular Drug Reviews, 2002
- Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52-week trialAmerican Heart Journal, 2002
- Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteersBritish Journal of Clinical Pharmacology, 2002
- No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase InhibitorThe Journal of Clinical Pharmacology, 2002
- Fibrates, dyslipoproteinaemia and cardiovascular diseaseCurrent Opinion in Lipidology, 1999
- Micronised fenofibrateAtherosclerosis, 1994